As mentioned above, 843 HER2-positive BC patients had been divided into three groups: group 1 (without trastuzumab treatment), group 2 (with trastuzumab treatment and low pre-NLR value) and group 3 (with trastuzumab treatment and high pre-NLR value). The gene discussed is ERBB2; the disease is breast cancer.